ARC-01 / Araris Biotech - LARVOL DELTA

Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting (GlobeNewswire) - "Araris Biotech AG...announced the company will deliver a poster presentation and an oral presentation at this year’s American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022, in New Orleans, Louisiana. The poster presentation highlights the company’s anti-CD79b antibody-drug conjugate (ADC) and the oral presentation, taking place during the conference’s minisymposium, will highlight late-breaking data on a Nectin-4 ADC generated using the company’s proprietary linker technology."

Late-breaking abstract • Preclinical • Oncology

Araris Biotech AG to Present Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire) - "Araris Biotech AG...announced the company will be presenting a scientific poster, as well as presenting preclinical data at the Minisymposium during the American Association for Cancer Research (AACR) Annual Meeting 2022....The poster will highlight preclinical data from Araris’ anti-CD79b antibody-drug conjugate (ADC) program, and the company will also present data on a Nectin-4 ADC."

Preclinical • Oncology

Araris Biotech AG to Present at 12th Annual World ADC Digital Conference (GlobeNewswire) - "Presentation highlights: ARC-01, Araris’ anti-CD79b ADC, was highly stable in human, monkey and rodent serum, as well as in vivo in mice and rats and showed mAb-like properties. ARC-01 showed superior anti-tumor efficacy in a head-to-head study compared to the FDA-approved polatuzumab vedotin (PV) using the identical antibody sequence and payload."

Preclinical • Oncology